Skip to main content

Advertisement

Table 1 Descriptive characteristics of study participants

From: Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response

  Mean ± standard deviation or N (%)
N (%) 595 (100)
Randomized to hydrochlorothiazide, N (%) 302 (51)
Age, years 49.3 ± 9.1
Male, N (%) 280 (47)
Black, N (%) 245 (41)
BMI, kg·m-2 30.6 ± 5.6
Hypertension duration, years 7.1 ± 7.2
Antihypertensive medication, N (%) 492 (91)
Current smoker, N (%) 69 (13)
Glucose, mg·dL-1 94.8 ± 10.5
Creatinine, mg·dL-1 0.9 ± 0.2
Serum ALT, U·L-1 29.1 ± 15.9
Plasma renin activity, ng·mL-1·hr-1 1.0 ± 1.2
Resting heart rate, beat·min-1 71.0 ± 10.2
Screening office systolic BP, mmHg 137.9 ± 13.8
Screening office diastolic BP, mmHg 89.5 ± 8.8
Pretreatment systolic blood pressure, mmHg 151.5 ± 13.8
Pretreatment diastolic blood pressure, mmHg 98.2 ± 6.3
  1. BMI, body mass index; ALT, alanine aminotransferase; BP, mmHg. Characteristics were measured at the screening visit except pretreatment systolic and diastolic BP and plasma renin activity were measured at the end of the drug-free washout period prior to initiating atenolol or hydrochlorothiazide therapy.